Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

@article{Pafili2014GevokizumabIT,
  title={Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?},
  author={Kalliopi Pafili and Nikolaos Papanas and Efstratios S Maltezos},
  journal={Expert opinion on investigational drugs},
  year={2014},
  volume={23 9},
  pages={1277-84}
}
INTRODUCTION Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. AREAS COVERED In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1β by binding to it. This is relevant, because this IL has been associated with β-cell toxicity in both diabetes types. Moreover… CONTINUE READING